ViiV Healthcare's Rukobia, or fostemsavir, was granted marketing authorization by European regulators as a treatment for multidrug-resistant HIV-1 infections in adults. Rukobia was cleared for use in patients who are unable to take a suppressive antiviral-regimen.
EU authorizes fostemsavir for multidrug-resistant HIV
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.